- 17% quarter-over-quarter growth with record VINIA® global sales orders in Q4 of USD 825k
- 485% year-over-year growth with total sales orders of USD 2.4M in 2021
- Continued success in VINIA® US pilot with USD 325k in sales orders in Q4, a 27% growth over Q3
Vancouver, British Columbia, and Rehovot, Israel–(Newsfile Corp. – January 6, 2022) – BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) today announces another strong quarter of sales growth for VINIA®, its nutrient-rich red grape supplement created through the Company’s proprietary BioFarming technology, in both Israel and the United States. The USD 825k of sales orders in Q4 from its direct-to-consumer ecommerce business represents a 17% increase over Q3 and are triple the sales orders from the same quarter in 2020. VINIA® sales orders in 2021 amounted to USD 2.4M, a nearly sixfold increase over 2020.
In Israel, where VINIA® is becoming synonymous with cardiovascular health and wellness, BioHarvest reported record sales orders of USD 501k in Q4, representing growth of 11% over Q3 and 84% over Q4 2020 – and total sales orders in 2021 were USD 1.73M, representing a 325% year-on-year growth.
Q4 sales orders in the ongoing US pilot program, launched in May 2021, totaled USD 325k, representing 27% growth over Q3 2021 and yielded a total sales order figure of USD 652k for the year.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109227
Powered by WPeMatico
